A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Cardiovascular and Cerebrovascular Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery

NCT00157716 Phase 2 COMPLETED

The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery

Details

Lead sponsor	Medicure
Phase	Phase 2
Status	COMPLETED
Enrolment	900
Start date	2004-04
Completion	2005-10

Conditions

• Coronary Artery Bypass Graft Surgery
• Myocardial Ischemia
• Reperfusion Injury
• Myocardial Revascularization

Interventions

• (MC-1) Pyridoxal-5'-phosphate

Primary outcomes

• Combined incidence of cardiovascular death, nonfatal myocardial infarction and nonfatal cerebral infarction on days up to and including post-operative day 30.

Countries

United States, Canada